Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer

NCT00521404 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT00521404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00521404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
Lead sponsor
Daiichi Sankyo
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2007
Completion date
August 20, 2010
Enrollment
65 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer